Trials / Completed
CompletedNCT06536595
Validity and Reliability of the Turkish Version of HAnDE
Validity and Reliability of the Turkish Version of the Hand Scleroderma Lived Experience Scale
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 77 (actual)
- Sponsor
- Gazi University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the present study was to translate and cross-culturally adapt The Hand Scleroderma Experienced Experience (HAnDE) Scale into the Turkish language and investigate its reliability and validity in Turkish-speaking patients with systemic sclerosis.
Detailed description
Objective: The aim of the present study was to translate and cross-culturally adapt The Hand Scleroderma Experienced Experience (HAnDE) Scale into the Turkish language and investigate its reliability and validity in Turkish-speaking patients with systemic sclerosis. Methods: The HAnDE was cross-culturally adapted according to Beaton's guideline. Participants completed the Turkish version of HAnDE scale (HAnDE-T), The Mouth Handicap in Systemic Sclerosis Scale (MHISS), 36 Item Short Form Survey (SF-36), Health Assessment Questionnaire (HAQ). Internal consistency of the HAnDE-T questionnaire was evaluated by Cronbach's alpha coefficient. Convergent validity was tested using Pearson's correlation coefficient. The construct validity of the HAnDE-T questionnaire was assessed by factor analysis. The construct validity of the HAnDE-T was evaluated by correlating the scores between HAnDE-T and HAQ, SF-36 PCS, SF-36 MCS and MHISS scores.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Scales | Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test. |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2022-06-01
- Completion
- 2024-01-01
- First posted
- 2024-08-05
- Last updated
- 2024-08-09
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06536595. Inclusion in this directory is not an endorsement.